RU93054168A - DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS - Google Patents

DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS

Info

Publication number
RU93054168A
RU93054168A RU93054168/14A RU93054168A RU93054168A RU 93054168 A RU93054168 A RU 93054168A RU 93054168/14 A RU93054168/14 A RU 93054168/14A RU 93054168 A RU93054168 A RU 93054168A RU 93054168 A RU93054168 A RU 93054168A
Authority
RU
Russia
Prior art keywords
dimer
apo
lipoprotein
aro
option
Prior art date
Application number
RU93054168/14A
Other languages
Russian (ru)
Other versions
RU2134696C1 (en
Inventor
Чиртори Чезаре
Франческини Гвидо
Абрамсен Ларс
Холмгрен Эрик
Лаке Матс
Нильссон Бъерн
Кмиелевска Йоанна
Линд Петер
Original Assignee
Каби Фармациа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9103701A external-priority patent/SE9103701D0/en
Application filed by Каби Фармациа АБ filed Critical Каби Фармациа АБ
Publication of RU93054168A publication Critical patent/RU93054168A/en
Application granted granted Critical
Publication of RU2134696C1 publication Critical patent/RU2134696C1/en

Links

Claims (1)

Предлагаемое изобретение относится к чистым димерам аро-липопротеина Al-Milano/Apo AI-M/Apo AI-M/, которые сначала были выделены из плазмы и охарактеризованы. Оно также относится к фармацевтическим составам, включающим Apo AI-M/Apo AI-M. Димер аро-липопротеина AI-M был получен в системе рекомбинантной Escherichia coli или выделен из плазмы носителей аро-липопротеина AI-Milano. Настоящее изобретение также включает способ лечения атеросклероза и сердечно-сосудистых заболеваний и использование димера в приготовлении лекарств. Лекарства, содержащие димер, могут быть использованы для лечения атеросклероза и сердечно-сосудистых заболеваний, а также для предотвращения тромбозов в различных клинических обстоятельствах как на артериальном, так и на венозном уровне. Димер также может действовать как про-лекарство для мономера.The present invention relates to pure Al-Milano / Apo AI-M / Apo AI-M / apo-lipoprotein dimers, which were first isolated from plasma and characterized. It also relates to pharmaceutical formulations comprising Apo AI-M / Apo AI-M. The AI-M aro-lipoprotein dimer was obtained in the recombinant Escherichia coli system or isolated from the plasma of AI-Milano apo-lipoprotein carriers. The present invention also includes a method of treating atherosclerosis and cardiovascular disease, and the use of a dimer in the preparation of drugs. Dimer-containing drugs can be used to treat atherosclerosis and cardiovascular diseases, as well as to prevent thrombosis in various clinical circumstances, both at the arterial and venous levels. A dimer may also act as a pro-drug for the monomer.
RU93054168A 1991-12-13 1992-12-11 Dimer of molecular variant of apo-lipoprotein, method of its preparing and pharmaceutical composition on said RU2134696C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (en) 1991-12-13 1991-12-13 apolipoprotein
SE9103701-0 1991-12-13
PCT/SE1992/000858 WO1993012143A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof

Publications (2)

Publication Number Publication Date
RU93054168A true RU93054168A (en) 1996-10-10
RU2134696C1 RU2134696C1 (en) 1999-08-20

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93054168A RU2134696C1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apo-lipoprotein, method of its preparing and pharmaceutical composition on said

Country Status (28)

Country Link
US (2) US5876968A (en)
EP (1) EP0571602B1 (en)
JP (1) JPH07502892A (en)
AT (1) ATE242269T1 (en)
AU (2) AU3175593A (en)
BG (1) BG61451B1 (en)
BR (1) BR9205640A (en)
CA (1) CA2103996C (en)
CZ (1) CZ289879B6 (en)
DE (1) DE69233092T2 (en)
DK (1) DK0571602T3 (en)
EE (1) EE03058B1 (en)
ES (1) ES2199939T3 (en)
FI (1) FI115771B (en)
HU (2) HU217203B (en)
IL (1) IL103956A (en)
MX (1) MX9207224A (en)
NO (1) NO315076B1 (en)
NZ (2) NZ280516A (en)
PL (3) PL171907B1 (en)
PT (1) PT571602E (en)
RO (1) RO115636B1 (en)
RU (1) RU2134696C1 (en)
SE (1) SE9103701D0 (en)
SG (1) SG47453A1 (en)
SK (1) SK86893A3 (en)
WO (1) WO1993012143A1 (en)
ZA (1) ZA928989B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
SE9203753D0 (en) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M
SE9500778D0 (en) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (en) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa NEW VARIANTS OF APOLIPOPROTEIN
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
SE9603068D0 (en) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
PT1290013E (en) 2000-04-21 2006-06-30 Amgen Inc DERIVATIVES OF APO-AI / AII PEPTIDES
BRPI0003386B8 (en) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
IL161110A0 (en) * 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
EP1461028A4 (en) * 2001-12-07 2007-07-25 Univ California Treatment for age-related macular degeneration
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP2006502976A (en) * 2002-05-17 2006-01-26 エスペリオン セラピューティクス，インコーポレイテッド Methods and compositions for treating ischemia-reperfusion
BR0310099A (en) 2002-05-17 2007-03-20 Esperion Therapeutics Inc method for treating dyslipidemia or a disease associated with dyslipidemia
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
PE20050438A1 (en) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California Helical synthetic peptides that stimulate cellular cholesterol efflux
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (en) * 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
WO2012047930A2 (en) * 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1890715A4 (en) 2005-04-29 2009-10-28 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007000924A1 (en) * 2005-06-28 2007-01-04 Osaka University Pharmaceutical composition comprising substance capable of inhibiting or promoting progranulin activity and screening method for substance capable of inhibiting or promoting progranulin activity
KR100719389B1 (en) 2005-10-18 2007-05-17 주식회사 녹십자 Method for manufacturing purified apolipoprotein A-I product from human plasma
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
EP2049137A4 (en) 2006-08-08 2013-05-01 Univ California Salicylanilides enhance oral delivery of therapeutic peptides
EP2057270A1 (en) * 2006-08-10 2009-05-13 Plantechno SRL In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009050266A2 (en) * 2007-10-19 2009-04-23 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
WO2009055538A1 (en) 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
KR20180094137A (en) 2009-05-05 2018-08-22 알닐람 파마슈티칼스 인코포레이티드 Lipid compositions
US8158601B2 (en) 2009-06-10 2012-04-17 Alnylam Pharmaceuticals, Inc. Lipid formulation
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
EP2367843B1 (en) * 2009-12-14 2014-10-08 Scil Proteins GmbH Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CN103096875B (en) 2010-06-03 2016-08-17 阿尔尼拉姆医药品有限公司 Biodegradable lipid for delivery of active agent
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
MX343907B (en) 2011-02-07 2016-11-28 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof.
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
JP6207507B2 (en) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Shortened tetranectin-apolipoprotein AI fusion protein, lipid particles containing the same, and uses thereof
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (en) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Hdl therapy markers.
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
DK3253785T3 (en) 2015-02-06 2019-07-08 Navigo Proteins Gmbh HOWEVER THE ENDED EGFR BINDING PROTEINS
US10808042B2 (en) 2015-07-16 2020-10-20 Navigo Proteins Gmbh Immunoglobulin-binding proteins and their use in affinity purification
CA2991815A1 (en) 2015-07-20 2017-01-26 Navigo Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017191252A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
JP6951417B2 (en) 2016-08-11 2021-10-20 レプリゲン・コーポレイションＲｅｐｌｉｇｅｎ Ｃｏｒｐｏｒａｔｉｏｎ FC-binding proteins for affinity chromatography, as well as affinity isolation matrices containing Fc-binding proteins and their use
EP3668549A1 (en) 2017-08-10 2020-06-24 Abionyx Pharma SA Apomers
EP3668600A1 (en) 2017-08-10 2020-06-24 Abionyx Pharma SA Cargomers
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
AU2021354095A1 (en) 2020-10-01 2023-06-08 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
JP2024514154A (en) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー Use of lipid-binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (en) * 1989-04-20 1991-09-20 Cesare Sirtori EXPRESSION OF APOLIPOPROTEIN AI AND APOLIPOPROTEIN AI-MILAN IN YEAST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE APOLIPOPROTEINS.
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein

Similar Documents

Publication Publication Date Title
RU93054168A (en) DIMER OF THE MOLECULAR OPTION OF ARO-LIPOPROTEIN, METHOD OF ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS
CA2103996A1 (en) Dimer of molecular variant of apolipoprotein and processes for the production thereof
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
RU93051522A (en) METHOD FOR TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASING THE LEVEL OF THE FACTOR CAUSING NECROSIS OF TUMOR CELLS
ES2170104T3 (en) INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS.
EA200100524A1 (en) AMIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS MEDICINES
FI101377B1 (en) Process for the preparation of N-alkylated 1,4-dihydropyridine compounds
DE69309790T2 (en) Cyclopentane perhydrophenanthrene-17-beta (3-furyl) -3 derivatives and pharmaceutical preparations thereof, for the treatment of cardiovascular diseases
FI961634A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
DE69621786T2 (en) AMINOTETRAL IN DERIVATIVE FOR THE TREATMENT OF HEART CIRCULAR DISEASE
DK0538690T3 (en) Arylquinolyl-substituted 1,4-dihydropyridine-dicarboxylic acid derivatives, process for their preparation in drug use
CA2065889A1 (en) Increasing the choroidal blood flow
ATE184287T1 (en) DERIVATIVES OF PEPTIDES THERAPEUTICALLY EFFECTIVE IN THE BLOOD CLOTTING CAScade, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
RU93057110A (en) APPENDECTOMY METHOD
RU94007839A (en) Method for selecting preparations in individual mode for treating angina
RU93021719A (en) METHOD OF TREATMENT OF THE RETINA
RU92016559A (en) DIALCOXY-PYRIDINYLBENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING OR TREATMENT, METHOD FOR PRODUCING THEM, USE AND INTERMEDIATE COMPOUNDS
RU96114084A (en) METHOD FOR TREATING ALLERGIC DISEASES
RU93052444A (en) MEDICINE BAN